Weight gain after orthotopic liver transplantation: Is nonalcoholic fatty liver disease cirrhosis a risk factor for greater weight gain?

Jasmine Kouz, Catherine Vincent, Aaron Leong, Marc Dorais, Agnès Räkel – 5 July 2014 – Posttransplant weight gain is common after orthotopic liver transplantation. We sought to determine the extent of weight gain at 5 years after transplantation in patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis versus patients with other types of cirrhosis (non‐NAFLD). We studied 126 liver transplants performed between 2005 and 2007 at Saint Luc Hospital, University of Montreal. Seventeen of the 126 patients (13.5%) had NAFLD cirrhosis.

Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization

Aparna Goel, Neil Mehta, Jennifer Guy, Nicholas Fidelman, Francis Yao, John Roberts, Norah Terrault – 5 July 2014 – Liver transplantation (LT) is the treatment of choice for patients with cirrhosis and hepatocellular carcinoma (HCC) not amenable to resection. Locoregional therapies for HCC are often used to reduce tumor burden, bridge patients to LT, and down‐stage HCC so that patients are eligible for LT. We hypothesized that prior endovascular antitumor therapy may increase the risk of hepatic artery (HA) and biliary complications after LT.

High early cardiovascular mortality after liver transplantation

Lisa B. VanWagner, Brittany Lapin, Josh Levitsky, John T. Wilkins, Michael M. Abecassis, Anton I. Skaro, Donald M. Lloyd‐Jones – 5 July 2014 – Cardiovascular disease (CVD) contributes to excessive long‐term mortality after liver transplantation (LT); however, little is known about early postoperative CVD mortality in the current era. In addition, there is no model for predicting early postoperative CVD mortality across centers.

Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition

Valerie Sapp, Leah Gaffney, Steven F. EauClaire, Randolph P. Matthews – 4 July 2014 – Nonalcoholic fatty liver disease (NAFLD), the accumulation of lipid within hepatocytes, is increasing in prevalence. Increasing fructose consumption correlates with this increased prevalence, and rodent studies directly support fructose leading to NAFLD. The mechanisms of NAFLD and in particular fructose‐induced lipid accumulation remain unclear, although there is evidence for a role for endoplasmic reticulum (ER) stress and oxidative stress.

Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition

Valerie Sapp, Leah Gaffney, Steven F. EauClaire, Randolph P. Matthews – 4 July 2014 – Nonalcoholic fatty liver disease (NAFLD), the accumulation of lipid within hepatocytes, is increasing in prevalence. Increasing fructose consumption correlates with this increased prevalence, and rodent studies directly support fructose leading to NAFLD. The mechanisms of NAFLD and in particular fructose‐induced lipid accumulation remain unclear, although there is evidence for a role for endoplasmic reticulum (ER) stress and oxidative stress.

Cost‐effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C

Emmanuel A. Tsochatzis, Catriona Crossan, Louise Longworth, Kurinchi Gurusamy, Manolo Rodriguez‐Peralvarez, Konstantinos Mantzoukis, Julia O'Brien, Evangelos Thalassinos, Vassilios Papastergiou, Anna Noel‐Storr, Brian Davidson, Andrew K. Burroughs – 4 July 2014 – The cost‐effectiveness of noninvasive tests (NITs) as alternatives to liver biopsy is unknown. We compared the cost‐effectiveness of using NITs to inform treatment decisions in adult patients with chronic hepatitis C (CHC).

Subscribe to